| Revista: | Brazilian Journal of Pharmaceutical Sciences |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000451322 |
| ISSN: | 1984-8250 |
| Autors: | Ayata, Nese1 Sezer, Ali Demir1 Bucak, Seyda2 Turanlı, Eda Tahir3 |
| Institucions: | 1Marmara University, Faculty of Pharmacy, Haydarpasa, Estambul. Turquía 2Yeditepe University, Faculty of Engineering, Atasehir, Estambul. Turquía 3İstanbul Technical University, Faculty of Science and Letters, Sariyer, Estambul. Turquía |
| Any: | 2020 |
| Volum: | 56 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | Gold coated magnetite nanoparticles were prepared and coated with ranibizumab as an ocular drug delivery system. The surface morphologies of the nanoparticles were determined by Scanning Electron Microscopy (SEM). The size and surface charge were determined by using the dynamic light scattering (DLS) technique. Crystallographic properties of the gold coated Fe3O4 nanoparticles were recorded on X-ray diffractometer (XRD) the XRD pattern of nanoparticlees were shown to have uniqe Fe3O4 and gold peaks. Conjugation of ranibizumab onto nanoparticles was achieved using the physical adsorption method. The amount of ranibizumab on the surface of the nanoparticles was determined by thermogravimetric analysis (TGA). In the in vitro release studies performed using UV spectroscopy; it was found that almost 60% of antibodies were released within the first 30 minutes. Antibody activity after release studies was also proved with ELISA. Non-toxicity of gold coated Fe3O4 particles were proved with MTT. Results of the studies, showed that the antibody conjugated magnetic nanoparticle system could be a potential treatment system for ocular diseases |
| Disciplines | Química |
| Paraules clau: | Química farmacéutica, Sistemas de liberación de fármacos, Anticuerpos monoclonales, Ranibizumab, Nanopartículas magnéticas |
| Keyword: | Medicinal chemistry, Drug delivery systems, Monoclonal antibodies, Ranibizumab, Magnetic nanoparticles |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
